ImmuDyne Appoints Chief Operating Officer/Chief Technology Officer
February 23 2017 - 8:30AM
ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader
in the development and marketing of OTC healthcare products, today
announced the appointment of Stefan Galluppi as its Chief
Operating Officer and Chief Technology Officer.
Mr. Galluppi has an extensive background in direct to consumer
marketing. In addition to building proprietary technology to
facilitate and optimize advertising campaigns for maximum
efficiency and profitability. Mr. Galluppi was also instrumental in
helping create the framework for an optimal back-end office
infrastructure which supported multiple National TV direct response
advertising campaigns rated among the top 10 on the national TV IMS
report rankings for performance.
“Immudyne had strong revenue growth in its direct to consumer
business in 2016, but we are looking to have considerably better
margins. As Immudyne’s COO and CTO, here in Q1 Stefan has been
focused on building out much more efficient advertising campaigns
which we believe will produce these higher
margins. We look to be in this position by the beginning of
Q2, at which time Immudyne plans on reigniting our marketing
budget in order to achieve our desired sales growth in each
of our direct to consumer businesses“, stated Mark
McLaughlin, President and Chief Executive Officer of
Immudyne.
Stefan Galluppi stated, “I’m very pleased to be
part of the Immudyne team and am confident we can create
meaningfully growth to the business and for our Immudyne
shareholders. We believe we can bring better profit margins across
our skincare lines, across our oral brand iNR Wellness
M.D. for immune System Support, as well as
with our new patented Shapiro M.D. line for male and
female hair loss which is planned to launch in late March.
Importantly, we can scale in each of these product offerings.”
About lmmuDyne
lmmuDyne, Inc. (the "Company") is a health and wellness company
which develops, manufactures, markets, and sells innovative
lifestyle products. The Company's lead products contain its
proprietary yeast beta glucans that have been shown through testing
and analysis to support the immune system. The Company's products
include once a day oral intake capsules as well as topical serums
and creams for skin application. lmmuDyne also has developed a
proprietary natural delivery technology for potential new market
opportunities. All of lmmuDyne's intellectual property is protected
by patents and/or trade secrets. Additional information can be
found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe
Harbor Act Disclaimer: Forward looking statements in this release
are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. Certain statements in
this press release, including projections with respect to
lmmuDyne's results of operations, may contain words such as
"anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "projects," "plans," "targets" and other
similar language and are considered forward-looking statements.
These statements are based on management's current expectations,
estimates, and forecasts. These forward-looking statements are
subject to important assumptions, risks and uncertainties, which
are difficult to predict and therefore the actual results may be
materially different from those discussed.
Contact:
ImmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901